Novartis (NVS) reported earnings per share (or EPS) of $1.21 on revenues of $12.9 billion in 4Q17. Further, its revenues are estimated to increase 5.0% to $12.1 billion in 1Q18 compared to revenues of $11.5 billion in 1Q17.
Novartis is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17. The chart below shows analysts’ recommendations for Novartis since February 2017.
Novartis’s (NVS) stock price has increased ~28.7% in the last 12 months. Analysts estimate the stock has a potential to return ~4.4% over the next 12 months. Wall Street analysts’ recommendations show a 12-month targeted price of $97.06 per share compared to its price of $92.98 per share on January 29, 2018.
Of the four analysts tracking Novartis ADR, two analysts recommend a “buy,” one analyst recommends a “hold,” and one analyst recommends a “sell.” The consensus rating for Novartis ADR is 2.5, representing a moderate buy for long-term growth investors and value investors.
There are 31 analysts covering Novartis stock listed on the SIX Swiss Exchange. Of these analysts, 15 analysts recommend a “buy,” 13 analysts recommend a “hold,” and three analysts recommend a “sell.” The consensus rating for Novartis stands at ~2.4, which represents a moderate buy for value investors.
The Vanguard Total International Stock ETF (VXUS) holds 7.4% of its total investments in healthcare companies. VXUS holds 0.7% of its total investments in Novartis AG (NVS), 0.4% in Novo Nordisk (NVO), 0.4% in Sanofi (SNY), and 0.3% in GlaxoSmithKline (GSK).